论文部分内容阅读
我院自1988年4月至1989年9月,用超分割放疗交替化疗治疗中晚其食管癌51例(Ⅰ组):超分割放疗每日2次,每次1.15Gy～1.25Gy,二次间隔≥6小时,每周照射5天,总量为69Gy～75Gy,分二疗程完成。化疗采用DDP20mg+5-Fu 500mg静滴3～5天,分别在放疗前和间隔期用。和常规放疗食管癌(Ⅱ组)回顾性比较,Ⅰ组完全缓解率显著高于Ⅱ组,且1、2年局部控制率以Ⅰ组为高。1、2、3年生存率分析,1年生存率Ⅰ组明显高于Ⅱ组。二组早、后期副作用无显著差别。初步认为,采用超分割放疗交替化疗能提高1年生存率,降低1、2年局部复发率,而不增加后期正常组织反应,明确结论尚待进一步研究。
In our hospital from April 1988 to September 1989, 51 patients with esophageal cancer (group I) were treated with hyperfractionated radiotherapy alternating chemotherapy in the middle and late: hyperfractionated radiotherapy twice a day for 1.15 Gy to 1.25 Gy twice. Interval ≥ 6 hours, 5 days per week, the total amount of 69Gy ~ 75Gy, completed in two courses. Chemotherapy with DDP20mg+5-Fu 500mg intravenous infusion for 3 to 5 days before radiotherapy and interval. Compared with conventional radiotherapy for esophageal cancer (Group II), the complete remission rate was significantly higher in Group I than in Group II, and the local control rate in Group 1 and 2 was higher in Group I. The 1-, 2-, and 3-year survival rate analysis showed that 1-year survival rate was significantly higher in group I than in group II. There were no significant differences in the side effects of the early and late periods in the two groups. It is initially believed that the use of hyperfractionated radiotherapy can increase the one-year survival rate, reduce the local recurrence rate of one and two years without increasing the normal tissue reaction in later stages, and the definite conclusion needs further study.